EGFR and neoplasm: Among patients treated with chemotherapy plus an anti-EGFR antibody (anti-EGFR antibody group), chemotherapy plus bevacizumab (bevacizumab group), and chemotherapy alone (chemotherapy-alone group), the median early tumor shrinkage was 0.3 to 0.4 in the anti-EGFR antibody group, 0.2 to 0.3 in the bevacizumab group, and 0.2 to 0.3 in the chemotherapy-alone group, regardless of the number of baseline targeted lesions or total tumor diameter (Figure 2).